Stifel Raises IQVIA (IQV) Price Target to $303

Stifel keeps its Buy rating on IQVIA Holdings and raises the price target to $303, a 12.04% upside from the current price.

By EarningsIQ Research Desk · Published Oct 15, 2026, 9:18 PM EDT · Updated Oct 16, 2026, 2:10 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Stifel raised its price target on IQVIA Holdings Inc. ($IQV) to $303 from $276 on October 14, 2026, and rates the stock "Buy".

Since the rating, $IQV is up 1.9% to date (from the $262.01 close on Oct 14, 2026).

IQV IQVIA Holdings Inc.

$266.90 +18.43% year to date

Daily close · Oct 16, 2026

Key Points

On October 14, 2026, Stifel reiterated its Buy rating on IQVIA Holdings Inc. (NYSE: IQV) and raised its price target from $276 to $303.
Stifel's $303 price target implies 12.04% upside from IQVIA Holdings Inc.'s ($IQV) current $270.45 share price.
IQVIA's stock recently traded around $270.45, which is about 10.7% below Stifel's new price target.
Several other firms also maintain positive ratings on IQVIA, with targets ranging from $300 to $329.

Get $IQV trade alerts by text

We text you when insiders, Congress or big funds trade $IQV. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated IQVIA Holdings Inc. alert may contain errors. Disclosures

Stifel has reiterated its Buy rating on IQVIA Holdings Inc. (NYSE: IQV) and raised its price target from $276 to $303 on October 14, 2026. This comes as the stock recently traded at about $270.45, which is approximately 10.7% below the new target set by Stifel.

Analyst rating track record

Stifel vs. the S&P 500

YTD return -13.79% hypothetical

All-time return -13.79% S&P 500 +1.28%

vs. S&P 500 -15.07% behind the index

Hypothetical returns from Stifel's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in IQVIA Holdings

Several other institutional investors have also shown interest in IQVIA. Blackrock Inc. reduced its holdings by 477,877 shares, ending with 14,549,693 shares valued at approximately $3.88 billion. Vanguard Capital Management LLC trimmed its stake by 122,405 shares, holding 10,905,053 shares worth about $2.91 billion. Meanwhile, State Street Corporation increased its position slightly, adding 31,403 shares for a total of 7,508,244 shares valued at around $2.00 billion.

IQVIA Holdings Inc. Stock Up 1.5%

IQVIA's stock is currently trading near $270.45, which is below its updated price target of $303. This positioning indicates potential upside if the stock moves towards the target. The shares have shown resilience in the healthcare sector, where IQVIA operates, providing vital services across multiple regions.

12-month forecast

$IQV price target

IQVIA Holdings Inc. daily closes and this analyst's $303 target. Not advice.

Recent Earnings

IQVIA reported trailing twelve-month revenue of approximately $16.98 billion and earnings per share (EPS) of $8.05. The company has demonstrated a revenue growth of 8.7% year-over-year and a net margin of 8.1%. The next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at IQVIA Holdings Inc.

Insider transactions include Chief Executive Officer Ari Bousbib, who sold 106,279 shares valued at about $26.09 million on July 29, 2026. Other officers also sold shares, including Bhavik Patel, who sold 1,855 shares for approximately $436,426 on July 31, and Walter Richard Staub III, who sold 5,500 shares worth about $1.28 million on August 3.

Analysts Set New Price Targets

On September 28, 2026, Truist Securities reiterated a Buy rating with a target of $329. RBC Capital maintained an Outperform rating with a target of $319 on September 29. Mizuho and Barclays both maintained their Outperform ratings, with targets of $300, reflecting confidence in IQVIA's growth potential.

About IQVIA Holdings Inc.

IQVIA Holdings Inc. provides essential clinical research services and healthcare intelligence to the life sciences sector and healthcare industries. The company operates through three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. With a workforce of around 94,000 employees, IQVIA plays a crucial role in advancing healthcare through data-driven insights.

Bottom Line

Investors should keep an eye on IQVIA as it approaches its next earnings report on November 3, 2026. Stifel's recent rating and target increase suggest confidence in the company's growth trajectory, while other analysts share similar positive sentiments.